Global Markets for Enzyme Inhibitors
Report Highlights
The global market for enzyme inhibitors should reach $179.9 billion by 2022 from $168 billion in 2017 at a compound annual growth rate (CAGR) of 1.4%, from 2017 to 2022.
Report Includes
- 55 data tables and 52 additional tables.
- An overview of the global markets for enzyme inhibitors.
- Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
- Detailed analysis of the enzyme inhibitors industry structure.
- A look at applications for enzyme inhibitors, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors.
- Coverage of significant patents and their allotments in each category.
- Profiles of major players in the industry, including:Abbott Laboratories, AbbVie Inc., Amgen, Inc., AstraZeneca PLC, Bayer Ag, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Cipla USA Inc.
Report Scope
Enzyme inhibitors drugs are drugs that help to treat chronic diseases such as cardiovascular disease, gastrointestinal disease, acquired immunodeficiency syndrome, cancer, hepatitis, men’s-health-related conditions (erectile dysfunction, benign prostatic hyperplasia, alopecia), diabetes and various others (rheumatoid arthritis, psoriasis, Parkinson’s disease, influenza, etc.). This report focuses on the global market of enzyme inhibitor drug products and provides an updated review including its applications in various arenas of disease sectors. The scope of the study is global. BCC Research analyzes each market and its application, new products and advancements, market projections and market shares. This study surveys each market in all the geographic regions including North America, Europe and emerging markets. The emerging market category covers all countries such as India, China, South Korea, Taiwan, Africa, Australia, New Zealand, Canada, Latin America and so forth.
Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the enzyme inhibitor drugs industry. Some of the major players of the market include, F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., AstraZeneca plc, Merck & Co., Gilead Sciences, Janssen Pharmaceuticals, ViiV Healthcare, Eli Lilly and Co., Takeda Pharmaceuticals, Bayer AG, Amgen Inc., AbbVie , Eisai Inc., Teva Pharmaceuticals Inc. and others.
BCC Research analyzes the current market situation by discussing the market drivers, restraints, challenges and opportunities. The market projections and market shares are examined for each region and type. The latest news pieces including new products, mergers and acquisitions in each market are also dealt with in sufficient detail. Also included in the report are relevant patent analysis and comprehensive profiles of companies that are dominant in the enzyme inhibitors industry.
The period of the current report saw an enormous number of new approvals and new indication approvals. New enzyme inhibitor categories gained entries in the market. In comparison with the last report, therefore, a number of new enzyme inhibitor types have been included in this report. They are integrase inhibitors, PCSK9 inhibitors, PARP inhibitors, PDE4 inhibitors, DPP-4 inhibitors and SGLT-2 inhibitors. Certain other categories that had mentionable markets were also included such as AChEIs, 5-ARI inhibitors, XOIs and MAOIs. The market had started to decline due to patent expiries since 2010–2011, and the trend was seen to accelerate during the period of the current report.
Excluded from this report are enzyme inhibitors used in other markets of diagnostics, pesticides and biotechnology.
Frequently Asked Questions (FAQs)
Analyst Credentials
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
Report Highlights
The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.
Report Highlights
-
During the forecast period, enzyme-inhibiting drugs are projected to be introduced for new indications including asthma and chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, hepatitis C and intermittent claudication.
-
Recent withdrawals of products in the COX-2 inhibitor class along with recent and future introductions of novel products in other classes will rearrange the market share of categories in the enzyme inhibitor sector. Overall, the market for products included in this report is expected to show an average annual growth rate (AAGR) of approximately 6.7% from 2005 to 2011, increasing from $29.2 billion to $43.1 billion.
-
Of all the inhibitor categories, COX-2 and PDE4 will see increases in revenue share for the period 2005 to 2011. Cox-2 inhibitors' share will grow from 12.7% to 18.9%, while PDE4 inhibitors will increase from zero in 2005 to 3.6% in 2011.